Regulatory T cells and TLR9 activation shape antibody formation to a secreted transgene product in AAV muscle gene transfer

Follicular Helper CD4 T Cells (T _FH )

Crotty, S. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101400 · Cited by 2,738 · see citing works

Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice

Kim, J. M., Rasmussen, J. P., & Rudensky, A. Y. (2006) · Nature Immunology · doi:10.1038/ni1428 · Cited by 1,827 · see citing works

Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector

Xiao, X., Li, J., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.11.8098-8108.1996 · Cited by 913 · see citing works

A Toll-Like Receptor 2 Ligand Stimulates Th2 Responses In Vivo, via Induction of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase and c-Fos in Dendritic Cells

Dillon, S. M., Agrawal, A., Dyke, T. E. V., Landreth, G. E., McCauley, L. K., Koh, A. J., Maliszewski, C. R., Akira, S., & Pulendran, B. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.8.4733 · Cited by 460 · see citing works

TLR-dependent T cell activation in autoimmunity

Mills, K. H. G. (2011) · Nature reviews. Immunology · doi:10.1038/nri3095 · Cited by 439 · see citing works

The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice

Zhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330 · see citing works

T follicular regulatory cells

Sage, P. T., & Sharpe, A. H. (2016) · Immunological Reviews · doi:10.1111/imr.12411 · Cited by 327 · see citing works

High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency

Ayuso, E., Mingozzi, F., Montané, J., León, X., Anguela, X. M., Haurigot, V., Edmonson, S. A., Africa, L. M., Zhou, S., High, K. A., et al. (2009) · Gene Therapy · doi:10.1038/gt.2009.157 · Cited by 279 · see citing works

CpG-depleted adeno-associated virus vectors evade immune detection

Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254 · see citing works

Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs

Ballas, Z. K., Krieg, A. Μ., Warren, T. L., Rasmussen, W. L., Davis, H. L., Waldschmidt, M., & Weiner, G. J. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.9.4878 · Cited by 250 · see citing works

The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9–dependent innate immune responses in the liver

Martino, A. T., Suzuki, M., Markusic, D. M., Zolotukhin, I., Ryals, R. C., Moghimi, B., Ertl, H. C. J., Muruve, D. A., Lee, B., & Herzog, R. W. (2011) · Blood · doi:10.1182/blood-2010-10-314518 · Cited by 246 · see citing works

Selective Utilization of Toll-like Receptor and MyD88 Signaling in B Cells for Enhancement of the Antiviral Germinal Center Response

Hou, B., Saudan, P., Ott, G. S., Wheeler, M. L., Ji, M., Kuzmich, L., Lee, L. M., Coffman, R. L., Bachmann, M. F., & DeFranco, A. L. (2011) · Immunity · doi:10.1016/j.immuni.2011.01.011 · Cited by 237 · see citing works

Suppression by TFR cells leads to durable and selective inhibition of B cell effector function

Sage, P. T., Ron‐Harel, N., Juneja, V. R., Sen, D. R., Maleri, S., Sungnak, W., Kuchroo, V. K., Haining, W. N., Chevrier, N., Haigis, M. C., et al. (2016) · Nature Immunology · doi:10.1038/ni.3578 · Cited by 236 · see citing works

Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer

Cao, O., Dobrzynski, E., Wang, L., Nayak, S., Mingle, B., Terhorst, C., & Herzog, R. W. (2007) · Blood · doi:10.1182/blood-2007-02-073304 · Cited by 220 · see citing works

Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotides

Mutwiri, G., Nichani, A., Babiuk, S., & Babiuk, L. A. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.02.022 · Cited by 207 · see citing works

From the Th1/Th2 Paradigm towards a Toll-Like Receptor/T-Helper Bias

Netea, M. G., van der Meer, J. W. M., Sutmuller, R. P. M., Adema, G. J., & Kullberg, B. J. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.10.3991-3996.2005 · Cited by 180 · see citing works

Innate Immune Responses to AAV Vectors

Rogers, G. L., Martino, A. T., Aslanidi, G. V., Jayandharan, G. R., Srivastava, A., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00194 · Cited by 178 · see citing works

Human Treg responses allow sustained recombinant adeno-associated virus–mediated transgene expression

Mueller, C., Chulay, J. D., Trapnell, B. C., Humphries, M., Carey, B., Sandhaus, R. A., McElvaney, N. G., Messina, L., Tang, Q., Rouhani, F. N., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci70314 · Cited by 169 · see citing works

Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1

Arruda, V. R., Schüttrumpf, J., Herzog, R. W., Nichols, T. C., Robinson, N. A., Lotfi, Y., Mingozzi, F., Xiao, W., Couto, L. B., & High, K. A. (2003) · Blood · doi:10.1182/blood-2003-05-1446 · Cited by 149 · see citing works

Influence of vector dose on factor IX-specific T and B cell responses in muscle-directed gene therapy

Herzog, R. W., Fields, P. A., Arruda, V. R., Brubaker, J. O., Armstrong, E., McClintock, D., Bellinger, D. A., Couto, L. B., Nichols, T. C., & High, K. A. (2002) · Human Gene Therapy · doi:10.1089/104303402760128513 · Cited by 147 · see citing works

Immune Responses to Intramuscular Administration of Alipogene Tiparvovec (AAV1-LPL ^S447X ) in a Phase II Clinical Trial of Lipoprotein Lipase Deficiency Gene Therapy

Ferreira, V., Twisk, J., Kwikkers, K., Aronica, E., Brisson, D., Methot, J., Petry, H., & Gaudet, D. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.169 · Cited by 137 · see citing works

Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer

Dobrzynski, E., Mingozzi, F., Liu, Y.-L., Bendo, E., Cao, O., Wang, L., & Herzog, R. W. (2004) · Blood · doi:10.1182/blood-2004-03-0847 · Cited by 135 · see citing works

Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies

Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., & Herzog, R. W. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302859 · Cited by 116 · see citing works

Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B

Arruda, V. R., Stedman, H. H., Haurigot, V., Buchlis, G., Baila, S., Favaro, P. M. B., Chen, Y.-F., Franck, H. W. G., Zhou, S., Wright, J. F., et al. (2010) · Blood · doi:10.1182/blood-2009-12-261156 · Cited by 115 · see citing works

Chemical structure and immunobiological activity of Porphyromonas gingivalis lipid A

Ogawa, T. (2007) · Frontiers in bioscience · doi:10.2741/2353 · Cited by 101 · see citing works

Monocyte‐derived dendritic cells promote T follicular helper cell differentiation

Chakarov, S., & Fazilleau, N. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201403841 · Cited by 96 · see citing works

Major role of local immune responses in antibody formation to factor IX in AAV gene transfer

Wang, L., Cao, O., Swalm, B., Dobrzynski, E., Mingozzi, F., & Herzog, R. W. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302539 · Cited by 95 · see citing works

Systemic protein delivery by muscle-gene transfer is limited by a local immune response

Wang, L., Dobrzynski, E., Schlachterman, A., Cao, O., & Herzog, R. W. (2005) · Blood · doi:10.1182/blood-2004-03-0848 · Cited by 94 · see citing works

Unique Roles of TLR9- and MyD88-Dependent and -Independent Pathways in Adaptive Immune Responses to AAV-Mediated Gene Transfer

Rogers, G. L., Suzuki, M., Zolotukhin, I., Markusic, D. M., Morel, L. M., Lee, B., Ertl, H. C. J., & Herzog, R. W. (2015) · Journal of Innate Immunity · doi:10.1159/000369273 · Cited by 85 · see citing works

Priming of T follicular helper cells by dendritic cells

Ballesteros‐Tato, A., & Randall, T. D. (2013) · Immunology and Cell Biology · doi:10.1038/icb.2013.62 · Cited by 81 · see citing works

Nonredundant Roles of IL-10 and TGF-β in Suppression of Immune Responses to Hepatic AAV-Factor IX Gene Transfer

Hoffman, B. E., Martino, A. T., Sack, B. K., Cao, O., Liao, G., Terhorst, C., & Herzog, R. W. (2011) · Molecular Therapy · doi:10.1038/mt.2011.33 · Cited by 72 · see citing works

Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells

NAYAK, S., CAO, O., HOFFMAN, B. E., COOPER, M., ZHOU, S., ATKINSON, M. A., & HERZOG, R. W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03548.x · Cited by 66 · see citing works

Ex Vivo Expanded Autologous Polyclonal Regulatory T Cells Suppress Inhibitor Formation in Hemophilia

Sarkar, D., Biswas, M., Liao, G., Seay, H. R., Perrin, G. Q., Markusic, D. M., Hoffman, B. E., Brusko, T. M., Terhorst, C., & Herzog, R. W. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.30 · Cited by 62 · see citing works

Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies

Fuchs, S. P., & Desrosiers, R. C. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.68 · Cited by 61 · see citing works

Factors influencing cross-presentation of non-self antigens expressed from recombinant adeno-associated virus vectors

Sarukhan, A., Soudais, C., Danos, O., & Jooss, K. U. (2001) · The Journal of Gene Medicine · doi:10.1002/jgm.175 · Cited by 60 · see citing works

MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV

Sudres, M., Ciré, S., Vasseur, V., Brault, L., Da Rocha, S., Boisgérault, F., Le Bec, C., Gross, D. A., Blouin, V., Ryffel, B., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.101 · Cited by 59 · see citing works

Gene therapy for hemophilia

Herzog, R. W. (2015) · Frontiers in bioscience · doi:10.2741/4324 · Cited by 56 · see citing works

Role of regulatory T cells in tolerance to coagulation factors

Cao, O., LoDuca, P. A., & Herzog, R. W. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03417.x · Cited by 54 · see citing works

Tolerance Induction to Cytoplasmic β-Galactosidase by Hepatic AAV Gene Transfer — Implications for Antigen Presentation and Immunotoxicity

Martino, A. T., Nayak, S., Hoffman, B. E., Cooper, M., Liao, G., Markusic, D. M., Byrne, B. J., Terhorst, C., & Herzog, R. W. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006376 · Cited by 54 · see citing works

Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease

Doerfler, P. A., Todd, A. G., Clément, N., Falk, D. J., Nayak, S., Herzog, R. W., & Byrne, B. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.103 · Cited by 54 · see citing works

The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer

Boisgérault, F., & Mingozzi, F. (2015) · Current Gene Therapy · doi:10.2174/1566523215666150630121750 · Cited by 54 · see citing works

Role of the Vector Genome and Underlying Factor IX Mutation in Immune Responses to AAV Gene Therapy for Hemophilia B

Rogers, G. L., Martino, A. T., Zolotukhin, I., Ertl, H. C., & Herzog, R. W. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-25 · Cited by 45 · see citing works

Muscle as a Target for Supplementary Factor IX Gene Transfer

Hoffman, B. E., Dobrzynski, E., Wang, L., Hirao, L. A., Mingozzi, F., Cao, O., & Herzog, R. W. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.042 · Cited by 44 · see citing works

Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B

Nayak, S., Sarkar, D., Perrin, G. Q., Moghimi, B., Hoffman, B. E., Zhou, S., Byrne, B. J., & Herzog, R. W. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00244 · Cited by 40 · see citing works

Dynamics of antigen presentation to transgene product-specific CD4+ T cells and of Treg induction upon hepatic AAV gene transfer

Perrin, G. Q., Zolotukhin, I., Sherman, A., Biswas, M., de Jong, Y. P., Terhorst, C., Davidoff, A. M., & Herzog, R. W. (2016) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2016.83 · Cited by 40 · see citing works

Immune Tolerance Induction to Factor IX through B Cell Gene Transfer: TLR9 Signaling Delineates between Tolerogenic and Immunogenic B Cells

Wang, X., Moghimi, B., Zolotukhin, I., Morel, L. M., Cao, O., & Herzog, R. W. (2014) · Molecular Therapy · doi:10.1038/mt.2014.43 · Cited by 31 · see citing works

Intrinsic Transgene Immunogenicity Gears CD8+ T-cell Priming After rAAV-Mediated Muscle Gene Transfer

Carpentier, M., Lorain, S., Chappert, P., Lalfer, M., Hardet, R., Urbain, D., Peccate, C., Adriouch, S., Garcı́a, L., Davoust, J. M., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.235 · Cited by 25 · see citing works

Cytotoxic T Lymphocyte Responses to Transgene Product, Not Adeno-Associated Viral Capsid Protein, Limit Transgene Expression in Mice

Siders, W., Shields, J. D., Kaplan, J. M., Lukason, M., Woodworth, L. A., Wadsworth, S., & Scaria, A. (2009) · Human Gene Therapy · doi:10.1089/hum.2008.055 · Cited by 21 · see citing works

Oral-tolerization Prevents Immune Responses and Improves Transgene Persistence Following Gene Transfer Mediated by Adeno-associated Viral Vector

Hardet, R., Chevalier, B., Dupaty, L., Naïmi, Y., Riou, G., Drouot, L., Jean, L., Salvetti, A., Boyer, O., & Adriouch, S. (2015) · Molecular Therapy · doi:10.1038/mt.2015.146 · Cited by 20 · see citing works

Immune Modulatory Cell Therapy for Hemophilia B Based on CD20-Targeted Lentiviral Gene Transfer to Primary B Cells

Wang, X., Herzog, R. W., Byrne, B. J., Kumar, S. R. P., Zhou, Q., Buchholz, C. J., & Biswas, M. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.03.005 · Cited by 19 · see citing works

Retroviral Vectors Induce Epigenetic Chromatin Modifications and IL-10 Production in Transduced B Cells via Activation of Toll-like Receptor 2

Ahangarani, R. R., Janssens, W., Carlier, V. A., VanderElst, L., VandenDriessche, T., Chuah, M., Jacquemin, M. G., & Saint‐Remy, J. (2010) · Molecular Therapy · doi:10.1038/mt.2010.275 · Cited by 18 · see citing works

Optimal Immunofluorescent Staining for Human Factor IX and Infiltrating T Cells following Gene Therapy for Hemophilia B

Rogers, G. L., & Hoffman, B. E. (2013) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-012 · Cited by 17 · see citing works

Continuous CD8 + T-Cell Priming by Dendritic Cell Cross-Presentation of Persistent Antigen following Adeno-Associated Virus-Mediated Gene Delivery

Xu, D., & Walker, C. M. (2011) · Journal of Virology · doi:10.1128/jvi.05375-11 · Cited by 14 · see citing works

Induction of immune tolerance to FIX by intramuscular AAV gene transfer is independent of the activation status of dendritic cells

Bharadwaj, A. S., Kelly, M., Kim, D., & Chao, H. (2009) · Blood · doi:10.1182/blood-2009-08-239509 · Cited by 7 · see citing works

Regulatory T Cells and Immune Tolerance to Coagulation Factor IX in the Context of Intramuscular AAV1 Gene Transfer

Kelly, M., Bharadwaj, A. S., Tacke, F., & Chao, H. (2009) · Molecular Therapy · doi:10.1038/mt.2009.269 · Cited by 5 · see citing works

Immune Responses to Viral Gene Therapy Vectors

Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788 · see citing works

AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer

Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641 · see citing works

Human Immune Responses to Adeno-Associated Virus (AAV) Vectors

Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357 · see citing works

Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper

Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 118 · see citing works

Exposure to wild-type AAV drives distinct capsid immunity profiles in humans

Kuranda, K., Jean-Alphonse, P., Leborgne, C., Hardet, R., Collaud, F., Marmier, S., Costa Verdera, H., Ronzitti, G., Veron, P., & Mingozzi, F. (2018) · Journal of Clinical Investigation · doi:10.1172/jci122372 · Cited by 104 · see citing works

Immune Response Mechanisms against AAV Vectors in Animal Models

Martino, A. T., & Markusic, D. M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.008 · Cited by 97 · see citing works

Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood

Smith, C. J., Ross, N., Kamal, A., Kim, K. Y., Kropf, E., Deschatelets, P., Francois, C., Quinn, W. J., Singh, I., Majowicz, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.999021 · Cited by 86 · see citing works

Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia

Monahan, P. E., Négrier, C., Tarantino, M. D., Valentino, L. A., & Mingozzi, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112471 · Cited by 85 · see citing works

Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy

Bertolini, T. B., Shirley, J. L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S. R. P., & Herzog, R. W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672449 · Cited by 80 · see citing works

Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models

Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 78 · see citing works

Adeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog

Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 70 · see citing works

Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy

Srivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 65 · see citing works

Codon-optimization in gene therapy: promises, prospects and challenges

Paremskaia, A. I., Kogan, A. A., Murashkina, A., Naumova, D. A., Satish, A., Abramov, I. S., Feoktistova, S. G., Mityaeva, O. N., Deviatkin, A. A., & Volchkov, P. (2024) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2024.1371596 · Cited by 66 · see citing works

Deep Parallel Characterization of AAV Tropism and AAV-Mediated Transcriptional Changes via Single-Cell RNA Sequencing

Brown, D. A., Altermatt, M., Dobreva, T., Chen, S., Wang, A. Z., Thomson, M. W., & Gradinaru, V. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.730825 · Cited by 58 · see citing works

Humoral immune responses to <scp>AAV</scp> gene therapy in the ocular compartment

Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52 · see citing works

Pompe disease gene therapy: neural manifestations require consideration of CNS directed therapy

Byrne, B. J., Fuller, D. D., Smith, B. K., Clement, N., Coleman, K., Cleaver, B., Vaught, L., Falk, D. J., McCall, A., & Corti, M. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.56 · Cited by 51 · see citing works

Innate immune sensing of adeno-associated virus vectors

Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50 · see citing works

Recombinant adeno-associated virus as a delivery platform for ocular gene therapy: A comprehensive review

Wang, J.-H., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.017 · Cited by 48 · see citing works

Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?

Ail, D., Malki, H., Zin, E. A., & Dalkara, D. (2023) · The Application of Clinical Genetics · doi:10.2147/tacg.s383453 · Cited by 40 · see citing works

TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer

Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35 · see citing works

Hepatotoxicity in Adeno-Associated Viral Vector Gene Therapy

Jagadisan, B., & Dhawan, A. K. (2023) · Current Hepatology Reports · doi:10.1007/s11901-023-00624-5 · Cited by 31 · see citing works

Retina-directed gene therapy: Achievements and remaining challenges

Biber, J., Gandor, C. L. A., Bećirović, E., & Michalakis, S. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108862 · Cited by 24 · see citing works

Factor VIII Trafficking to CD4+ T cells Shapes its Immunogenicity and Requires Several Types of Antigen Presenting Cells

Kaczmarek, R., Piñeros, A. R., Patterson, P. E., Bertolini, T. B., Perrin, G. Q., Sherman, A., Born, J., Arisa, S., Arvin, M. C., Kamocka, M. M., et al. (2023) · Blood · doi:10.1182/blood.2022018937 · Cited by 19 · see citing works

Alpha 1 Antitrypsin Gene Therapy Extends the Lifespan of Lupus-Prone Mice

Elshikha, A. S., Yuan, Y., Lu, Y., Chen, M., Abboud, G., Akbar, M. A., Plate, H., Wolney, H., Hoffmann, T., Tagari, E., et al. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.10.007 · Cited by 15 · see citing works

Emerging optogenetics technologies in biomedical applications

Ren, H., Cheng, Y., Wen, G., Wang, J., & Zhou, M. (2023) · Smart Medicine · doi:10.1002/smmd.20230026 · Cited by 14 · see citing works

Chemical modification of AAV9 capsid with N-ethyl maleimide alters vector tissue tropism

Mulcrone, P. L., Lam, A. K., Frabutt, D. A., Zhang, J., Chrzanowski, M., Herzog, R. W., & Xiao, W. (2023) · Scientific Reports · doi:10.1038/s41598-023-35547-0 · Cited by 13 · see citing works

Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer

Li, N., Kumar, S. R. P., Cao, D., Muñoz-Melero, M., Arisa, S., Brian, B. A., Greenwood, C. M., Yamada, K., Duan, D., & Herzog, R. W. (2024) · Viruses · doi:10.3390/v16101507 · Cited by 14 · see citing works

Emerging approaches to induce immune tolerance to therapeutic proteins

Noel, J. C., Lagassé, D., Golding, B., & Sauna, Z. E. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.10.002 · Cited by 13 · see citing works

Adeno‐associated viral vector gene therapy: Challenges for the paediatric hepatologist

Jagadisan, B., & Dhawan, A. K. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12326 · Cited by 7 · see citing works

The presence of CpGs in AAV gene therapy vectors induces a plasmacytoid dendritic cell-like population very early after administration

Glenn, J. D., Negash, H., Henry, W., Qian, R., Liu, Y., Danos, O., Bruder, J. T., & Karumuthil-Melethil, S. (2024) · Cellular Immunology · doi:10.1016/j.cellimm.2024.104823 · Cited by 6 · see citing works

Organoid transduction using recombinant adeno‐associated viral vectors: Challenges and opportunities

Belova, L., Лавров, А. В., & Smirnikhina, S. (2022) · BioEssays · doi:10.1002/bies.202200055 · Cited by 5 · see citing works

Viral vectors in neurodegenerative diseases: immune responses and therapeutic applications

Wang, Y., Mu, S., & Liu, F. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1603125 · Cited by 3 · see citing works

AAV Immunotoxicity: Implications in Anti-HBV Gene Therapy

Jacobs, R., Dogbey, D. M., Mnyandu, N., Neves, K., Barth, S., Arbuthnot, P. B., & Maepa, M. B. (2023) · Microorganisms · doi:10.3390/microorganisms11122985 · Cited by 3 · see citing works

Gene Therapy and Gene Editing for Cancer Therapeutics

Mandal, S., & Tiwari, P. K. (2020) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-7998-6530-8.ch004 · Cited by 2 · see citing works

Gene Therapy and Gene Editing for Cancer Therapeutics

Mandal, S., & Tiwari, P. K. (2023) · IGI Global eBooks · doi:10.4018/979-8-3693-3026-5.ch033 · Cited by 2 · see citing works

A comprehensive analysis of scRNA-Seq and RNA-Seq unveils B cell immune suppression in the AAV-loaded brain

Wu, S., Xue, L., Li, X., Wang, Y., Zhu, Y., Luo, Y., Sun, J., Jin, T., Shu, W., & Wang, Z. (2025) · Immunologic Research · doi:10.1007/s12026-025-09609-6 · Cited by 1 · see citing works

Detection of Humoral Response to Transgene Protein and Gene Editing Reagents

Buchlis, G., & Gorovits, B. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch12 · Cited by 1 · see citing works

Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint

Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783

Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint

Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783.1

TLR9-Activating CpG-B ODN but Not TLR7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer

Butterfield, J. S. S., Biswas, M., Shirley, J. L., Kumar, S. R. P., Sherman, A., Terhorst, C., Ling, C., & Herzog, R. W. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.013 · Cited by 35 · see citing works

696. TLR9 Signaling Mediates Transgene Antibody Formation

Ashley, S. N., McMenamin, D., Draper, C., & Wilson, J. M. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)33504-3

615. A Self-Limiting but Prolonged Inflammatory Response to AAV-Factor IX Gene Transfer to Skeletal Muscle

(2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.155

Systemic protein delivery by muscle-gene transfer is limited by a local immune response

Wang, L., Dobrzynski, E., Schlachterman, A., Cao, O., & Herzog, R. W. (2005) · Blood · doi:10.1182/blood-2004-03-0848 · Cited by 94 · see citing works

AAV Vector Dose Determines TLR9 Dependence of CD8+ T Cell Response to Transgene Product

Li, N., Bertolini, T., & Herzog, R. W. (2020) · Blood · doi:10.1182/blood-2020-141054 · Cited by 5 · see citing works